Genotoxicity of topoisomerase II inhibitors: An anti-infective perspective

Toxicology

Volumn 254, Issue 3, 2008, Pages 192-198

  Smart, Daniel J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

H2AX; Anti infective agents; DNA damage response; DNA double strand breaks; Genotoxicity thresholds; Topoisomerase II

Indexed keywords

3 HYDROXYQUINAZOLINE 2,4 DIONE; AMINOCOUMARIN DERIVATIVE; ANTIINFECTIVE AGENT; CINODINE; CLEROCIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; HISTONE GAMMA H2AX; HISTONE H2AX; ISOTHIAZOPYRIDONE; MICROCIN; MOLECULAR MARKER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG RESEARCH; ENZYME INHIBITION; GENOTOXICITY; HUMAN; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; FLUOROQUINOLONES; HISTONES; HUMANS; MUTAGENICITY TESTS; MUTAGENS; PHOSPHORYLATION;

EUKARYOTA; MAMMALIA;

EID: 56349125194     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.08.023     Document Type: Review

References (84)

1. Achanta G., and Huang P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res. 64 17 (2004) 6233-6239
2. Albertini S., et al. Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis 10 4 (1995) 343-351
3. Anderson V.E., and Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 7 5 (2001) 337-353
4. Aranha O., Wood Jr. D.P., and Sarkar F.H. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin. Cancer Res. 6 3 (2000) 891-900
5. Aranha O., et al. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int. J. Oncol. 22 4 (2003) 787-794
6. Azarova A.M., et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. U.S.A. 104 22 (2007) 11014-11019
7. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 6922 (2003) 499-506
8. Bassing C.H., and Alt F.W. H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 3 2 (2004) 149-153
9. Bredberg A., Brant M., and Jaszyk M. Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells. Antimicrob. Agents Chemother. 35 3 (1991) 448-450
10. Burma S., Chen B.P., Murphy M., Kurimasa A., and Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276 45 (2001) 42462-42467
11. Bush K. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 10 Suppl. 4 (2004) 10-17
12. Canman C.E., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 5383 (1998) 1677-1679
13. Celeste A., et al. Genomic instability in mice lacking histone H2AX. Science 296 5569 (2002) 922-927
14. Celeste A., et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat. Cell Biol. 5 7 (2003) 675-679
15. D'Arpa P., Beardmore C., and Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50 21 (1990) 6919-6924
16. Daboussi F., Dumay A., Delacote F., and Lopez B.S. DNA double-strand break repair signaling: the case of RAD51 post-translational regulation. Cell Signal. 14 12 (2002) 969-975
17. Degrassi F., Fiore M., and Palitti F. Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs. Curr. Med. Chem. Anticancer Agents 4 4 (2004) 317-325
18. Elhajouji A., Van Hummelen P., and Kirsch-Volders M. Indications for a threshold of chemically induced aneuploidy in vitro in human lymphocytes. Environ. Mol. Mutagen. 26 4 (1995) 292-304
19. Elhajouji A., Tibaldi F., and Kirsch-Volders M. Indication for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes. Mutagenesis 12 3 (1997) 133-140
20. Elsea S.H., McGuirk P.R., Gootz T.D., Moynihan M., and Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob. Agents Chemother. 37 10 (1993) 2179-2186
21. Elsea S.H., Westergaard M., Burden D.A., Lomenick J.P., and Osheroff N. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry 36 10 (1997) 2919-2924
22. Farhadi A., et al. Modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on neutrophil reactive oxygen species production in presence of a novel antioxidant, rebamipide. Dig. Dis. Sci. 47 6 (2002) 1342-1348
23. Felix C.A., Kolaris C.P., and Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) 5 9-10 (2006) 1093-1108
24. Forterre P., Gribaldo S., Gadelle D., and Serre M.C. Origin and evolution of DNA topoisomerases. Biochimie 89 4 (2007) 427-446
25. Hahm K.B., Lee K.J., Kim J.H., Cho S.W., and Chung M.H. Helicobacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide. Dig. Dis. Sci. 43 9 Suppl. (1998) 72S-77S
26. Halicka H.D., et al. Histone H2AX phosphorylation after cell irradiation with UV-B: relationship to cell cycle phase and induction of apoptosis. Cell Cycle 4 2 (2005) 339-345
27. Halicka, H.D., et al. Working title: 'Fluoroquinolones lower constitutive H2AX and ATM phosphorylation in TK6 lymphoblastoid cells via modulation of intracellular redox status', submitted to Pharmacological Reports.
28. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
29. Herbold B.A., Brendler-Schwaab S.Y., and Ahr H.J. Ciprofloxacin: in vivo genotoxicity studies. Mutat. Res. 498 1-2 (2001) 193-205
30. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 6835 (2001) 366-374
31. Hsiang Y.H., Jiang J.B., and Liu L.F. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol. Pharmacol. 36 3 (1989) 371-376
32. Huang X., Traganos F., and Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle 2 6 (2003) 614-619
33. Huang X., et al. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 58 2 (2004) 99-110
34. Huang X., et al. Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis. Cell Prolif. 38 4 (2005) 223-243
35. Huang X., Tanaka T., Kurose A., Traganos F., and Darzynkiewicz Z. Constitutive histone H2AX phosphorylation on Ser-139 in cells untreated by genotoxic agents is cell-cycle phase specific and attenuated by scavenging reactive oxygen species. Int. J. Oncol. 29 2 (2006) 495-501
36. Ismail I.H., and Hendzel M.J. The gamma-H2A, X: is it just a surrogate marker of double-strand breaks or much more?. Environ. Mol. Mutagen. 49 1 (2008) 73-82
37. Itoh T., Mitsumori K., Kawaguchi S., and Sasaki Y.F. Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test. Mutat. Res. 603 2 (2006) 135-144
38. Jeggo P.A., and Lobrich M. DNA double-strand breaks: their cellular and clinical impact?. Oncogene 26 56 (2007) 7717-7719
39. Karanjawala Z.E., and Lieber M.R. DNA damage and aging. Mech. Ageing Dev. 125 6 (2004) 405-416
40. Kirkland D.J., and Muller L. Interpretation of the biological relevance of genotoxicity test results: the importance of thresholds. Mutat. Res. 464 1 (2000) 137-147
41. Kirsch-Volders M., Aardema M., and Elhajouji A. Concepts of threshold in mutagenesis and carcinogenesis. Mutat. Res. 464 1 (2000) 3-11
42. Kresse H., Belsey M.J., and Rovini H. The antibacterial drugs market. Nat. Rev. Drug Discov. 6 1 (2007) 19-20
43. Kurose A., et al. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A 68 1 (2005) 1-9
44. Lee J.H., and Paull T.T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26 56 (2007) 7741-7748
45. Liu L.F., Liu C.C., and Alberts B.M. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19 3 (1980) 697-707
46. Luger K., Rechsteiner T.J., Flaus A.J., Waye M.M., and Richmond T.J. Characterization of nucleosome core particles containing histone proteins made in bacteria. J. Mol. Biol. 272 3 (1997) 301-311
47. Lutz W.K. Dose-response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes. Mutat. Res. 405 2 (1998) 117-124
48. Lynch A., et al. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 18 4 (2003) 345-353
49. MacPhail S.H., et al. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int. J. Radiat. Biol. 79 5 (2003) 351-358
50. Mao Y., Desai S.D., Ting C.Y., Hwang J., and Liu L.F. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 276 44 (2001) 40652-40658
51. Maxwell A. DNA gyrase as a drug target. Trends Microbiol. 5 3 (1997) 102-109
52. McClendon A.K., and Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623 1-2 (2007) 83-97
53. McQueen C.A., Way B.M., Queener S.M., Schluter G., and Williams G.M. Study of potential in vitro and in vivo genotoxicity in hepatocytes of quinolone antibiotics. Toxicol. Appl. Pharmacol. 111 2 (1991) 255-262
54. Miclau T., Edin M.L., Lester G.E., Lindsey R.W., and Dahners L.E. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J. Orthop. Res. 16 4 (1998) 509-512
55. Mills K.D., Ferguson D.O., and Alt F.W. The role of DNA breaks in genomic instability and tumorigenesis. Immunol. Rev. 194 (2003) 77-95
56. Moreau N.J., Robaux H., Baron L., and Tabary X. Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II. Antimicrob. Agents Chemother. 34 10 (1990) 1955-1960
57. Muller L., and Kasper P. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res. 464 1 (2000) 19-34
58. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6 1 (2007) 29-40
59. Riches L.C., Lynch A.M., and Gooderham N.J. Early events in the mammalian response to DNA double-strand breaks. Mutagenesis (2008) (Epub doi:10.1093/mutage/gen039)
60. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273 10 (1998) 5858-5868
61. Rogakou E.P., Boon C., Redon C., and Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146 5 (1999) 905-916
62. Rouse J., and Jackson S.P. Interfaces between the detection, signaling, and repair of DNA damage. Science 297 5581 (2002) 547-551
63. Scott S.P., and Pandita T.K. The cellular control of DNA double-strand breaks. J. Cell Biochem. 99 6 (2006) 1463-1475
64. Sedelnikova O.A., Pilch D.R., Redon C., and Bonner W.M. Histone H2AX in DNA damage and repair. Cancer Biol. Ther. 2 3 (2003) 233-235
65. Sedelnikova O.A., et al. Delayed kinetics of DNA double-strand break processing in normal and pathological aging. Aging Cell. 7 1 (2008) 89-100
66. Smart D.J., et al. Assessment of DNA double-strand breaks and γH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res. 641 1-2 (2008) 43-47
67. Smart D.J., Halicka H.D., Traganos F., Darzynkiewicz Z., and Williams G.M. Ciprofloxacin-induced G2 arrest and apoptosis in TK6 lymphoblastoid cells is not dependent on DNA double-strand break formation. Cancer Biol. Ther. 7 1 (2008) 113-119
68. Somekh E., Douer D., Shaked N., and Rubinstein E. In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J. Pharmacol. Exp. Ther. 248 1 (1989) 415-418
69. Strumberg D., et al. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell Biol. 20 11 (2000) 3977-3987
70. Sung P.A., Libura J., and Richardson C. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions. DNA Repair (Amst) 5 9-10 (2006) 1109-1118
71. Tanaka T., Halicka H.D., Huang X., Traganos F., and Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 5 17 (2006) 1940-1945
72. Tanaka T., Kurose A., Halicka H.D., Traganos F., and Darzynkiewicz Z. 2-Deoxy-d-glucose reduces the level of constitutive activation of ATM and phosphorylation of histone H2AX. Cell Cycle 5 8 (2006) 878-882
73. Tanaka T., et al. Extent of constitutive histone H2AX phosphorylation on Ser-139 varies in cells with different TP53 status. Cell Prolif. 39 4 (2006) 313-323
74. Tse-Dinh Y.C. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect. Disord. Drug Targets 7 1 (2007) 3-9
75. Uziel T., et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 22 20 (2003) 5612-5621
76. Vilenchik M.M., and Knudson A.G. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl. Acad. Sci. U.S.A. 100 22 (2003) 12871-12876
77. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65 (1996) 635-692
78. Weterings E., and Chen D.J. The endless tale of non-homologous end-joining. Cell Res. 18 1 (2008) 114-124
79. Williams G.M., et al. Nonlinearities in 2-acetylaminofluorene exposure responses for genotoxic and epigenetic effects leading to initiation of carcinogenesis in rat liver. Toxicol. Sci. 45 2 (1998) 152-161
80. Williams G.M., et al. Diethylnitrosamine exposure-responses for DNA ethylation, hepatocellular proliferation, and initiation of carcinogenesis in rat liver display non-linearities and thresholds. Arch. Toxicol. 73 7 (1999) 394-402
81. Williams G.M., Iatropoulos M.J., and Jeffrey A.M. Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by the DNA-reactive carcinogens 2-acetylaminofluorene and diethylnitrosamine. Toxicol. Pathol. 28 3 (2000) 388-395
82. Williams G.M., Iatropoulos M.J., and Jeffrey A.M. Thresholds for the effects of 2-acetylaminofluorene in rat liver. Toxicol. Pathol. 32 Suppl. 2 (2004) 85-91
83. Wilstermann A.M., and Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem. 3 3 (2003) 321-338
84. Wu J., and Liu L.F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res. 25 21 (1997) 4181-4186